Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin』s effects following an acute myocardial infarction

INGELHEIM, Germany & INDIANAPOLIS, US — (BUSINESS WIRE) — Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Cli…